The NCPE recommends that nintedanib (Ofev®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

The NCPE recommends that avelumab in combination with axitinib not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*

The Beneluxa collaboration has issued a joint statement with the Nordic Pharmaceutical Forum. 

The NCPE recommends that pembrolizumab be considered for reimbursement if cost effectiveness can be improved relative to existing treatments*.

The NCPE recommends that neratinib (Nerlynx®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

The NCPE recommends that Onasemnogene abeparvovec (Zolgensma®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.*

The NCPE recommends that pembrolizumab in combination with axitinib not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*

The NCPE recommends that tafamidis not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

The NCPE recommends that atezolizumab in combination with carboplatin and etoposide for the first-line treatment of adult patients with ES-SCLC is not considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

The NCPE recommends that voretigene neparvovec (Luxturna®) is not considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*